| Literature DB >> 35202563 |
Federico Tessadori1, Karen Duran2, Karen Knapp3, Matthias Fellner3, Sarah Smithson4, Ana Beleza Meireles4, Mariet W Elting5, Quinten Waisfisz5, Anne O'Donnell-Luria6, Catherine Nowak7, Jessica Douglas7, Anne Ronan8, Theresa Brunet9, Urania Kotzaeridou10, Shayna Svihovec11, Margarita S Saenz11, Isabelle Thiffault12, Florencia Del Viso13, Patrick Devine14, Shannon Rego14, Jessica Tenney15, Arie van Haeringen16, Claudia A L Ruivenkamp16, Saskia Koene16, Stephen P Robertson17, Charulata Deshpande18, Rolph Pfundt19, Nienke Verbeek20, Jiddeke M van de Kamp21, Janneke M M Weiss22, Anna Ruiz23, Elisabeth Gabau24, Ehud Banne25, Alexander Pepler26, Armand Bottani27, Sacha Laurent28, Michel Guipponi28, Emilia Bijlsma16, Ange-Line Bruel29, Arthur Sorlin30, Mary Willis31, Zoe Powis32, Thomas Smol33, Catherine Vincent-Delorme34, Diana Baralle35, Estelle Colin36, Nicole Revencu37, Eduardo Calpena38, Andrew O M Wilkie38, Maya Chopra39, Valerie Cormier-Daire40, Boris Keren41, Alexandra Afenjar42, Marcello Niceta43, Alessandra Terracciano44, Nicola Specchio45, Marco Tartaglia43, Marlene Rio46, Giulia Barcia46, Sophie Rondeau46, Cindy Colson47, Jeroen Bakkers48, Peter D Mace3, Louise S Bicknell49, Gijs van Haaften50.
Abstract
Chromatin is essentially an array of nucleosomes, each of which consists of the DNA double-stranded fiber wrapped around a histone octamer. This organization supports cellular processes such as DNA replication, DNA transcription, and DNA repair in all eukaryotes. Human histone H4 is encoded by fourteen canonical histone H4 genes, all differing at the nucleotide level but encoding an invariant protein. Here, we present a cohort of 29 subjects with de novo missense variants in six H4 genes (H4C3, H4C4, H4C5, H4C6, H4C9, and H4C11) identified by whole-exome sequencing and matchmaking. All individuals present with neurodevelopmental features of intellectual disability and motor and/or gross developmental delay, while non-neurological features are more variable. Ten amino acids are affected, six recurrently, and are all located within the H4 core or C-terminal tail. These variants cluster to specific regions of the core H4 globular domain, where protein-protein interactions occur with either other histone subunits or histone chaperones. Functional consequences of the identified variants were evaluated in zebrafish embryos, which displayed abnormal general development, defective head organs, and reduced body axis length, providing compelling evidence for the causality of the reported disorder(s). While multiple developmental syndromes have been linked to chromatin-associated factors, missense-bearing histone variants (e.g., H3 oncohistones) are only recently emerging as a major cause of pathogenicity. Our findings establish a broader involvement of H4 variants in developmental syndromes.Entities:
Keywords: histone H4; intellectual disability; microcephaly; neurodevelopmental disorder; nucleosome; zebrafish
Mesh:
Substances:
Year: 2022 PMID: 35202563 PMCID: PMC9069069 DOI: 10.1016/j.ajhg.2022.02.003
Source DB: PubMed Journal: Am J Hum Genet ISSN: 0002-9297 Impact factor: 11.025
Figure 1H4 variants identified in the cohort
(A) Highly recurrent variants were found in six different H4 genes (H4C3, H4C4, H4C5, H4C6, H4C9, and H4C11), which all encode an identical protein. Aggregate prevalence of disease-causing amino acid changes is also shown. The N-terminal methionine is cleaved from histone H4, and therefore all numbering is relative to the mature polypeptide, in keeping with the protein literature.
(B) The affected residues of H4 (orange ribbon) either cluster to the N-terminal α-helix facing toward DNA (cluster 1, purple spheres) or are located in regions buried within the nucleosome core (cluster 2, orange spheres). Size of sphere indicates the relative prevalence of substitutions affecting that residue.
Variants identified in H4 genes
| 1 | 6: 26,104,044 | c.97C>G | p.Pro33Ala | Pro32Ala | 23.1 | 0.526 | |
| 2 | 6: 26,104,045 | c.98C>T | p.Pro33Leu | Pro32Leu | 25.7 | 0.438 | |
| 3 | 6: 26,104,221 | c.274A>C | p.Lys92Gln | Lys91Gln | 26.6 | 0.706 | |
| 1 | 6: 26,188,955 | c.122G>A | p.Arg41His | Arg40His | 23.9 | 0.459 | |
| 1 | 6: 26,204,739 | c.95A>C | p.Lys32Thr | Lys31Thr | 26.6 | 0.523 | |
| 1 | 6: 26,204,742 | c.98C>G | p.Pro33Arg | Pro32Arg | 25.3 | 0.541 | |
| 1 | 6: 26,204,750 | c.106C>T | p.Arg36Trp | Arg35Trp | 26.6 | 0.494 | |
| 1 | 6: 26,204,757 | c.113T>C | p.Leu38Pro | Leu37Pro | 27.5 | 0.659 | |
| 4 | 6: 26,204,765 | c.121C>T | p.Arg41Cys | Arg40Cys | 26.6 | 0.446 | |
| 7 | 6: 26,204,780 | c.136C>T | p.Arg46Cys | Arg45Cys | 26.3 | 0.589 | |
| 2 | 6: 26,204,939 | c.295T>C | p.Tyr99His | Tyr98His | 26.9 | 0.317 | |
| 1 | 6: 26,240,708 | c.283G>A | p.Gly95Arg | Gly94Arg | 24.5 | 0.677 | |
| 1 | 6: 27,139,430 | c.122G>T | p.Arg41Leu | Arg40Leu | 26.7 | 0.628 | |
| 2 | 6: 27,139,535 | c.227A>G | p.His76Arg | His75Arg | 25.3 | 0.754 | |
| 1 | 6: 27,824,245 | c.121C>T | p.Arg41Cys | Arg40Cys | 25.8 | 0.541 |
RefSeq IDs: GenBank: NM_003542.4 (H4C3), GenBank: NM_003539.4 (H4C4), GenBank: NM_003545.3 (H4C5), GenBank: NM_003540.4 (H4C6), GenBank: NM_003495.2 (H4C9), GenBank: NM_021968.4 (H4C11).
Note on nomenclature: to refer to the residues belonging to this study, HGVS Variant nomenclature would include Methionine-1 (Met1) at the translation initiating site, e.g., H4C3 Pro33Ala (c.97C>G [p.Pro33Ala]). However, as the research field of epigenetics and oncohistones typically drops this first post-translationally removed methionine, we have also done so. Therefore, the above-mentioned example (included in this study) is referred to as H4C3 Pro32Ala.
Clinical features of individuals in the H4 cohort
| Intellectual disability | 29/29 (100%) |
| Developmental delay | 29/29 (100%) |
| Hypotonia | 10/29 (34%) |
| Seizures | 5/29 (17%) |
| Autism | 5/29 (17%) |
| Ataxia | 4/29 (14%) |
| Microcephaly—prenatal onset | 2/19 (11%) |
| Microcephaly—postnatal | 20/29 (69%) |
| Short stature | 11/29 (38%) |
| Failure to thrive | 11/29 (38%) |
| Craniosynostosis | 2/29 (7%) |
| Digit anomalies | 4/29 (14%) |
| Vertebral anomalies | 4/27 (15%) |
| Hypertelorism | 5/29 (17%) |
| Upslanting palpebral fissures | 3/29 (10%) |
| Broad nasal tip | 11/29 (38%) |
| Thin upper lip/vermillion | 4/29 (14%) |
| Teeth anomalies | 6/29 (21%) |
| Recurrent infections | 4/29 (14%) |
| Visual impairment | 17/28 (61%) |
| Hearing impairment | 7/29 (24%) |
| Age range | 10 months – 52 years (median 10 years 11 months) |
Figure 2Clinical characteristics of individuals with histone H4 gene variants
(A) Individuals with variants in histone H4 genes demonstrate a reduction in height, weight, and brain growth (OFC, occipitofrontal circumference); the latter significantly progresses as the individuals age. There are no detectable genotype-phenotype patterns separating by the specific histone H4 gene or variant cluster. ∗∗∗∗p < 0.0001.
(B) Facial dysmorphism affecting midline structures is noticeable among the cohort, but highly variable, with no obvious genotype-phenotype correlation.
(C) Individuals can present with abnormalities in the appearance and position of teeth (for example, P5, P25). A recurring feature present in several individuals is a noticeable gap between the upper central incisors.
(D) Individuals with variants in histone H4 genes also show a spectrum of toe anomalies, ranging from no anomalies present (for example, P21) through to severe 2–3 toe (P1, P28) or 3–4 toe (P25) syndactyly, which can be bilateral. Toes can also be short (P19, P28).
Figure 3H4 variants induce developmental defects in zebrafish embryos
(A) Phenotypical characterization in 28 hpf embryos. Representative images of observed phenotypes in zebrafish embryos 28 hpf microinjected with mRNA encoding either wild-type or identified variants at the one-cell stage. The different classes are defined on general development and necrosis. Arrowhead, cephalic necrosis; arrow, curved tail.
(B and C) High magnification examples of cephalic necrosis (B) and curved tail (C) phenotypes.
(D and E) Quantification of the phenotypical classification as described in (A). Variants reported in (D) were microinjected with 50 pg/embryo, and additional testing with 100 pg/embryo is reported in (E). Data marked with a hash symbol was previously published in Tessadori et al. Fisher’s exact test: ns, not significant; p > 0.05; ∗p < 0.05; ∗∗∗∗p < 0.0001. Scale bars: 100 μm (A); 50 μm (B and C).